Innovative Bispecific Nanobody Therapy Targeting ACE2 Surface Glycoprotein for Coronavirus Acute Respiratory Syndrome

VHH-P665 is a humanized nanobody-based bispecific antibody designed to target the angiotensin converting enzyme 2 (ACE2) surface glycoprotein, a critical entry point for SARS-CoV-2. Currently in the Biological Testing stage, VHH-P665 comprises a fully human monoclonal IgG1 fused to a single-domain antibody, engineered for high affinity and selectivity. By engaging distinct epitopes of the viral Spike protein, this program offers a novel therapeutic approach for coronavirus acute respiratory syndrome, leveraging advanced nanobody engineering to disrupt virus-host interactions. VHH-P665 holds promise for the treatment and prevention of severe respiratory disease caused by coronavirus infection.

Licensing Opportunity

VHH-P665 is available for out-licensing and partnership opportunities. We welcome inquiries from organizations interested in collaborating to advance this innovative therapeutic candidate for coronavirus acute respiratory syndrome.

Development Phase

Modality

VHH-P665 is constructed as a bispecific antibody, combining a human monoclonal IgG1 backbone with a C-terminally fused, humanized single-domain nanobody. This architecture harnesses the benefits of nanobodies—such as small molecular size, high tissue penetration, structural stability, and the ability to access cryptic epitopes. The IgG1 portion provides extended serum half-life and effector functionality, while the affinity-matured nanobody enhances binding specificity to the SARS-CoV-2 Spike protein. The L234A and L235A Fc modifications are designed to minimize unwanted immune activation. The unique structural integration of VHH-P665 may facilitate superior distribution to inflamed lung tissues and durable viral neutralization in the context of coronavirus acute respiratory syndrome.

Target

ACE2 Surface glycoprotein is a membrane-bound protein crucial for regulating several physiological processes. It is highly expressed in epithelial cells of the lung, intestine, kidney, and blood vessels. In coronavirus acute respiratory syndrome, ACE2 Surface glycoprotein serves as the principal entry receptor for SARS-CoV-2, enabling viral attachment and subsequent cell entry. By targeting ACE2 Surface glycoprotein, VHH-P665 aims to disrupt this critical virus-host interface, preventing infection of susceptible cells. Owing to its vital role in viral pathogenesis, ACE2 Surface glycoprotein has emerged as a high-value therapeutic target. The strategic targeting of ACE2 Surface glycoprotein by VHH-P665 not only offers direct anti-viral effects but also positions the program as a potential platform technology for a range of respiratory pathogens utilizing similar entry mechanisms.

Mechanism of Action

VHH-P665 acts by binding to two distinct epitopes on the receptor binding domain of the Spike protein, thereby blocking its interaction with ACE2 Surface glycoprotein. This dual-epitope engagement inhibits viral attachment and fusion, halting the entry of SARS-CoV-2 into host cells. As a viral fusion and attachment inhibitor, VHH-P665 impedes the initial steps of infection, intercepting the virus at the mucosal surface. The nanobody platform underlying VHH-P665 allows for further modular optimization—including adaptation into antibody-drug conjugates or other bispecific formats—to expand its antiviral and therapeutic capabilities. This mechanism provides a foundational strategy to counter coronavirus acute respiratory syndrome and potentially other emerging viral threats.

Coronavirus Acute Respiratory Syndrome

Coronavirus acute respiratory syndrome refers to the severe respiratory illness caused by highly pathogenic coronaviruses, including SARS-CoV-2. The global burden of this disease continues to be significant, with widespread outbreaks leading to high morbidity and mortality across diverse populations. Current therapeutic approaches include supportive care, antivirals, and immunomodulatory treatments, but limitations persist, such as variable efficacy and emerging drug resistance. No universally effective, targeted therapies exist for severe or refractory cases, highlighting an urgent unmet medical need. Nanobody-based agents like VHH-P665 offer a differentiated mechanism by directly interfering with viral cell entry processes. This innovative modality holds potential to provide rapid neutralization of the virus, reduce disease severity, and complement existing therapeutic regimens. The development of VHH-P665 represents a promising avenue for addressing the gaps in both prophylactic and therapeutic interventions for coronavirus acute respiratory syndrome.